Ignite Creation Date:
2025-12-24 @ 9:42 PM
Ignite Modification Date:
2025-12-30 @ 1:03 PM
Study NCT ID:
NCT03912532
Status:
COMPLETED
Last Update Posted:
2025-07-03
First Post:
2019-04-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
Sponsor:
NGM Biopharmaceuticals, Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-05-16
Start Date Type:
ACTUAL
Primary Completion Date:
2021-03-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-03-29
Completion Date Type:
ACTUAL
First Submit Date:
2019-04-09
First Submit QC Date:
None
Study First Post Date:
2019-04-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-03-07
Results First Submit QC Date:
None
Results First Post Date:
2025-07-03
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-16
Last Update Post Date:
2025-07-03
Last Update Post Date Type:
ACTUAL